The evaluation of acute vascular damage induced by platinum-based chemotherapy

The evaluation of acute vascular damage induced by platinum-based chemotherapy - Platinum-based chemotherapy and vascular damage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012956

Enrollment

100

Registered

2014-01-25

Start date

2010-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological cancer

Interventions

The patients exhibiting hypertriglyceridemia during chemotherapy were administered Bezafibrate No medication with bezafibrate for the patients exhibiting hypertriglyceridemia during chemotherapy. the

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ovarian cancer or endometrial cancer patients who are going to receive adjuvant chemotherapy after surgical treatment.

Exclusion criteria

Exclusion criteria: Participants who had received prior treatment for cancer and those with a history of cardiovascular disease (myocardial infarction, stroke, peripheral arterial thrombosis) or decompensated diabetes were excluded from this study. The exclusion criteria also included a history of clinically significant gastrointestinal, liver or gallbladder disease, treatment with lipid- or glucose-lowering agents and the use of hormone replacement therapy within the previous one year.

Design outcomes

Primary

Measure	Time frame
The change of the flow-mediated dilation (FMD), serum pentraxin-3	—

Countries

Japan

Contacts

Public ContactAkiko Tanabe

Osaka Medical College Obstetrics and Gynecology

gyn074@poh.osaka-med.ac.jp+81-72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026